-
1
-
-
79953283868
-
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
-
Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69(3):570-580.
-
(2011)
Ann Neurol
, vol.69
, Issue.3
, pp. 570-580
-
-
Shi, M.1
Bradner, J.2
Hancock, A.M.3
-
2
-
-
84885699313
-
Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease
-
Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013;70(10):1277-1287.
-
(2013)
JAMA Neurol
, vol.70
, Issue.10
, pp. 1277-1287
-
-
Kang, J.H.1
Irwin, D.J.2
Chen-Plotkin, A.S.3
-
3
-
-
84868585835
-
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders
-
Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69(11):1445-1452.
-
(2012)
Arch Neurol
, vol.69
, Issue.11
, pp. 1445-1452
-
-
Hall, S.1
Ohrfelt, A.2
Constantinescu, R.3
-
4
-
-
79951720856
-
alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
-
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10(3):230-240.
-
(2011)
Lancet Neurol
, vol.10
, Issue.3
, pp. 230-240
-
-
Mollenhauer, B.1
Locascio, J.J.2
Schulz-Schaeffer, W.3
Sixel-Doring, F.4
Trenkwalder, C.5
Schlossmacher, M.G.6
-
5
-
-
84871077687
-
Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects
-
Mollenhauer B, Trautmann E, Taylor P, et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett 2013;532:44-48.
-
(2013)
Neurosci Lett
, vol.532
, pp. 44-48
-
-
Mollenhauer, B.1
Trautmann, E.2
Taylor, P.3
-
6
-
-
77950223687
-
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
-
Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133(Pt 3):713-726.
-
(2010)
Brain
, vol.133
, pp. 713-726
-
-
Hong, Z.1
Shi, M.2
Chung, K.A.3
-
7
-
-
78649990079
-
Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease
-
Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75(20):1766-1772.
-
(2010)
Neurology
, vol.75
, Issue.20
, pp. 1766-1772
-
-
Tokuda, T.1
Qureshi, M.M.2
Ardah, M.T.3
-
8
-
-
84862916400
-
Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease
-
Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2011;7(4):215-222.
-
(2011)
J Clin Neurol
, vol.7
, Issue.4
, pp. 215-222
-
-
Park, M.J.1
Cheon, S.M.2
Bae, H.R.3
Kim, S.H.4
Kim, J.W.5
-
9
-
-
82355191922
-
CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease
-
Sierks MR, Chatterjee G, McGraw C, Kasturirangan S, Schulz P, Prasad S. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 2011;3(12):1188-1196.
-
(2011)
Integr Biol (Camb)
, vol.3
, Issue.12
, pp. 1188-1196
-
-
Sierks, M.R.1
Chatterjee, G.2
McGraw, C.3
Kasturirangan, S.4
Schulz, P.5
Prasad, S.6
-
10
-
-
85017330543
-
Phosphorylated α -synuclein in Parkinson's disease: correlation depends on disease severity
-
Stewart T, Sossi V, Aasly J, et al. Phosphorylated α -synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol 2015;31:3-7.
-
(2015)
Acta Neuropathol
, vol.31
, pp. 3-7
-
-
Stewart, T.1
Sossi, V.2
Aasly, J.3
-
11
-
-
72849127362
-
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease
-
Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24(15):2203-2210.
-
(2009)
Mov Disord
, vol.24
, Issue.15
, pp. 2203-2210
-
-
Compta, Y.1
Marti, M.J.2
Ibarretxe-Bilbao, N.3
-
12
-
-
84955726381
-
Neurodegenerative CSF markers in genetic and sporadic PD: classification and prediction in a longitudinal study
-
Brockmann K, Schulte C, Deuschle C, et al. Neurodegenerative CSF markers in genetic and sporadic PD: classification and prediction in a longitudinal study. Parkinsonism Relat Disord 2015;21:1427-1434.
-
(2015)
Parkinsonism Relat Disord
, vol.21
, pp. 1427-1434
-
-
Brockmann, K.1
Schulte, C.2
Deuschle, C.3
-
13
-
-
79960613150
-
Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias
-
Parnetti L, Chiasserini D, Bellomo G, et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011;26(8):1428-1435.
-
(2011)
Mov Disord
, vol.26
, Issue.8
, pp. 1428-1435
-
-
Parnetti, L.1
Chiasserini, D.2
Bellomo, G.3
-
14
-
-
78349237282
-
CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment
-
Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25(15):2682-2685.
-
(2010)
Mov Disord
, vol.25
, Issue.15
, pp. 2682-2685
-
-
Montine, T.J.1
Shi, M.2
Quinn, J.F.3
-
15
-
-
77955073900
-
Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes
-
Sussmuth SD, Uttner I, Landwehrmeyer B, et al. Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. Mov Disord 2010;25(9):1284-1288.
-
(2010)
Mov Disord
, vol.25
, Issue.9
, pp. 1284-1288
-
-
Sussmuth, S.D.1
Uttner, I.2
Landwehrmeyer, B.3
-
16
-
-
58149469520
-
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
-
Ohrfelt A, Grognet P, Andreasen N, et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 2009;450(3):332-335.
-
(2009)
Neurosci Lett
, vol.450
, Issue.3
, pp. 332-335
-
-
Ohrfelt, A.1
Grognet, P.2
Andreasen, N.3
-
17
-
-
77958071837
-
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study
-
Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81(10):1080-1086.
-
(2010)
J Neurol Neurosurg Psychiatry
, vol.81
, Issue.10
, pp. 1080-1086
-
-
Alves, G.1
Bronnick, K.2
Aarsland, D.3
-
18
-
-
47049100511
-
Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies
-
Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008;64(10):850-855.
-
(2008)
Biol Psychiatry
, vol.64
, Issue.10
, pp. 850-855
-
-
Parnetti, L.1
Tiraboschi, P.2
Lanari, A.3
-
19
-
-
79960353168
-
CSF alpha-synuclein, tau, and amyloid beta in Parkinson's disease
-
author's reply 81-83.
-
Shi M, Zhang J. CSF alpha-synuclein, tau, and amyloid beta in Parkinson's disease. Lancet Neurol 2011;10(8):681; author's reply 81-83.
-
(2011)
Lancet Neurol
, vol.10
, Issue.8
, pp. 681
-
-
Shi, M.1
Zhang, J.2
-
20
-
-
80054115170
-
Amyloid-beta and tau biomarkers in Parkinson's disease-dementia
-
Buongiorno M, Compta Y, Marti MJ. Amyloid-beta and tau biomarkers in Parkinson's disease-dementia. J Neurol Sci 2011;310(1-2):25-30.
-
(2011)
J Neurol Sci
, vol.310
, Issue.1-2
, pp. 25-30
-
-
Buongiorno, M.1
Compta, Y.2
Marti, M.J.3
-
21
-
-
84879411933
-
Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study
-
Compta Y, Pereira JB, Rios J, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013;19(8):717-724.
-
(2013)
Parkinsonism Relat Disord
, vol.19
, Issue.8
, pp. 717-724
-
-
Compta, Y.1
Pereira, J.B.2
Rios, J.3
-
22
-
-
27144549543
-
Cognitive profile of patients with newly diagnosed Parkinson disease
-
Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65(8):1239-1245.
-
(2005)
Neurology
, vol.65
, Issue.8
, pp. 1239-1245
-
-
Muslimovic, D.1
Post, B.2
Speelman, J.D.3
Schmand, B.4
-
23
-
-
27844469751
-
A systematic review of prevalence studies of dementia in Parkinson's disease
-
Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20(10):1255-1263.
-
(2005)
Mov Disord
, vol.20
, Issue.10
, pp. 1255-1263
-
-
Aarsland, D.1
Zaccai, J.2
Brayne, C.3
-
24
-
-
8844233579
-
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology
-
Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4):601-607.
-
(2004)
Neuron
, vol.44
, Issue.4
, pp. 601-607
-
-
Zimprich, A.1
Biskup, S.2
Leitner, P.3
-
25
-
-
8844266996
-
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
-
Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44(4):595-600.
-
(2004)
Neuron
, vol.44
, Issue.4
, pp. 595-600
-
-
Paisan-Ruiz, C.1
Jain, S.2
Evans, E.W.3
-
26
-
-
84863287993
-
Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers
-
Aasly JO, Shi M, Sossi V, et al. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology 2012;78(1):55-61.
-
(2012)
Neurology
, vol.78
, Issue.1
, pp. 55-61
-
-
Aasly, J.O.1
Shi, M.2
Sossi, V.3
-
27
-
-
84856970318
-
DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function
-
Shi M, Furay AR, Sossi V, et al. DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2012;33(4):836e5-836e7.
-
(2012)
Neurobiol Aging
, vol.33
, Issue.4
, pp. 836e5-836e7
-
-
Shi, M.1
Furay, A.R.2
Sossi, V.3
-
28
-
-
84907162800
-
Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
-
Aasly JO, Johansen KK, Bronstad G, et al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci 2014;6:248.
-
(2014)
Front Aging Neurosci
, vol.6
, pp. 248
-
-
Aasly, J.O.1
Johansen, K.K.2
Bronstad, G.3
-
29
-
-
0042591659
-
status and recommendations
-
The Unified Parkinson's Disease Rating Scale (UPDRS)
-
The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18(7):738-750.
-
(2003)
Mov Disord
, vol.18
, Issue.7
, pp. 738-750
-
-
-
30
-
-
61449165975
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results
-
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-2170.
-
(2008)
Mov Disord
, vol.23
, Issue.15
, pp. 2129-2170
-
-
Goetz, C.G.1
Tilley, B.C.2
Shaftman, S.R.3
-
31
-
-
0014082977
-
Parkinsonism: onset, progression and mortality
-
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-442.
-
(1967)
Neurology
, vol.17
, Issue.5
, pp. 427-442
-
-
Hoehn, M.M.1
Yahr, M.D.2
-
32
-
-
0025086894
-
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. the Parkinson Study Group
-
Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. the Parkinson Study Group. Neurology 1990;40(10):1529-1534.
-
(1990)
Neurology
, vol.40
, Issue.10
, pp. 1529-1534
-
-
Jankovic, J.1
McDermott, M.2
Carter, J.3
-
33
-
-
34447633928
-
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort
-
Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130(Pt 7):1787-1798.
-
(2007)
Brain
, vol.130
, pp. 1787-1798
-
-
Williams-Gray, C.H.1
Foltynie, T.2
Brayne, C.E.3
Robbins, T.W.4
Barker, R.A.5
-
34
-
-
84917679725
-
Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
-
Taymans JM, Baekelandt V. Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. Front Genet 2014;5:382.
-
(2014)
Front Genet
, vol.5
, pp. 382
-
-
Taymans, J.M.1
Baekelandt, V.2
-
35
-
-
81255127582
-
Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?
-
Biernacka JM, Armasu SM, Cunningham JM, Ahlskog JE, Chung SJ, Maraganore DM. Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility? Parkinsonism Relat Disord 2011;17(10):730-736.
-
(2011)
Parkinsonism Relat Disord
, vol.17
, Issue.10
, pp. 730-736
-
-
Biernacka, J.M.1
Armasu, S.M.2
Cunningham, J.M.3
Ahlskog, J.E.4
Chung, S.J.5
Maraganore, D.M.6
-
36
-
-
78651440972
-
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?
-
Greggio E, Bisaglia M, Civiero L, Bubacco L. Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? Mol Neurodegener 2011;6(1):6.
-
(2011)
Mol Neurodegener
, vol.6
, Issue.1
, pp. 6
-
-
Greggio, E.1
Bisaglia, M.2
Civiero, L.3
Bubacco, L.4
-
38
-
-
0037118259
-
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein
-
Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002;34(4):521-533.
-
(2002)
Neuron
, vol.34
, Issue.4
, pp. 521-533
-
-
Giasson, B.I.1
Duda, J.E.2
Quinn, S.M.3
Zhang, B.4
Trojanowski, J.Q.5
Lee, V.M.6
-
39
-
-
79957636327
-
Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau
-
Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 2011;31(21):7604-7618.
-
(2011)
J Neurosci
, vol.31
, Issue.21
, pp. 7604-7618
-
-
Waxman, E.A.1
Giasson, B.I.2
-
40
-
-
5444255434
-
Stages in the development of Parkinson's disease-related pathology
-
Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318(1):121-134.
-
(2004)
Cell Tissue Res
, vol.318
, Issue.1
, pp. 121-134
-
-
Braak, H.1
Ghebremedhin, E.2
Rub, U.3
Bratzke, H.4
Del Tredici, K.5
-
41
-
-
72849151978
-
When does Parkinson's disease begin?
-
Gaig C, Tolosa E. When does Parkinson's disease begin? Mov Disord. 2009;24(suppl 2):S656-S664.
-
(2009)
Mov Disord.
, vol.24
, pp. S656-S664
-
-
Gaig, C.1
Tolosa, E.2
|